TISIDB

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane
Domain	PF00067 Cytochrome P450
Function	Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.

> Gene Ontology [ TOP ]
Biological Process	GO:0006694 steroid biosynthetic process GO:0006702 androgen biosynthetic process GO:0006704 glucocorticoid biosynthetic process GO:0007548 sex differentiation GO:0008202 steroid metabolic process GO:0008207 C21-steroid hormone metabolic process GO:0008209 androgen metabolic process GO:0008211 glucocorticoid metabolic process GO:0010817 regulation of hormone levels GO:0016125 sterol metabolic process GO:0034754 cellular hormone metabolic process GO:0042180 cellular ketone metabolic process GO:0042445 hormone metabolic process GO:0042446 hormone biosynthetic process GO:0042448 progesterone metabolic process GO:1901615 organic hydroxy compound metabolic process
Molecular Function	GO:0004497 monooxygenase activity GO:0004508 steroid 17-alpha-monooxygenase activity GO:0005506 iron ion binding GO:0008395 steroid hydroxylase activity GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016829 lyase activity GO:0016830 carbon-carbon lyase activity GO:0016832 aldehyde-lyase activity GO:0019825 oxygen binding GO:0020037 heme binding GO:0046906 tetrapyrrole binding GO:0047442 17-alpha-hydroxyprogesterone aldolase activity
Cellular Component	GO:0030424 axon GO:0043025 neuronal cell body GO:0044297 cell body

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04913 Ovarian steroidogenesis hsa04917 Prolactin signaling pathway hsa00140 Steroid hormone biosynthesis hsa01100 Metabolic pathways
Reactome	R-HSA-193048: Androgen biosynthesis R-HSA-211859: Biological oxidations R-HSA-211897: Cytochrome P450 - arranged by substrate type R-HSA-211976: Endogenous sterols R-HSA-194002: Glucocorticoid biosynthesis R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-196071: Metabolism of steroid hormones R-HSA-211945: Phase 1 - Functionalization of compounds R-HSA-209943: Steroid hormones

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04913 Ovarian steroidogenesis
hsa04917 Prolactin signaling pathway
hsa00140 Steroid hormone biosynthesis
hsa01100 Metabolic pathways

Reactome

R-HSA-193048: Androgen biosynthesis
R-HSA-211859: Biological oxidations
R-HSA-211897: Cytochrome P450 - arranged by substrate type
R-HSA-211976: Endogenous sterols
R-HSA-194002: Glucocorticoid biosynthesis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-196071: Metabolism of steroid hormones
R-HSA-211945: Phase 1 - Functionalization of compounds
R-HSA-209943: Steroid hormones

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CYP17A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CYP17A1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CYP17A1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.229	0.21
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.426	0.436
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.081	0.831
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.112	0.015
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.397	0.111
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.749	0.475
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-1.692	0.333
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.818	0.422
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.147	0.59

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CYP17A1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYP17A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYP17A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYP17A1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYP17A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CYP17A1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CYP17A1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CYP17A1
Name	cytochrome P450, family 17, subfamily A, polypeptide 1
Aliases	P450C17; CPT7; S17AH; Steroid 17-alpha-monooxygenase; CYP17; cytochrome P450, subfamily XVII (steroid 17-alp ......
Chromosomal Location	10q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CYP17A1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CYP17A1.

ID	Name	Drug Type	Targets	#Targets
DB00157	NADH	Small Molecule	AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......	144
DB00396	Progesterone	Small Molecule	AR, CYP17A1, ESR1, NR1I2, NR3C1, NR3C2, OPRK1, ORM1, PGR, SHBG	10
DB05812	Abiraterone	Small Molecule	CYP17A1	1

Browse CYP17A1